NASDAQ:LNTH
Lantheus (LNTH-Q)
Financials
Technical Analysis
Buy, Sell or Hold?
Related posts
Nervous markets await Nvidia
Apr 9, 2025, 12:00 amThis summary was created by AI, based on 2 opinions in the last 12 months.
Lantheus (LNTH) has demonstrated significant price volatility historically, prompting cautious advice from experts regarding tax loss harvesting strategies. Despite negative momentum following recent earnings, the potential for a bounce exists due to upcoming positive announcements during the holiday season. The company surpassed EPS expectations, reporting $1.69 against a forecast of $1.54, alongside revenue growth of 23% year-over-year, driven by strong sales of PYLARIFY and DEFINITY. Management's strategic partnerships, including with Perspective Therapeutics, bolster its position in the radiopharmaceutical sector. Notably, the company is currently debt-free, has ample cash reserves, and generates solid free cash flow, contributing to its attractiveness as a hold at current levels.
LNTH has historically had some big price swings so we think selling it for a tax loss does has some risk. Momentum has of course been negative since the earnings but any positive news at all sets up the potential for a positive bounce going into Christmas. Usually we would be fine with a tax loss harvest strategy but we think this one is too 'bouncy' and the timeframe before year end too short. We would consider it a hold at current levels.
Unlock Premium - Try 5i Free
LNTH beat EPS estimates of $1.54 coming in at $1.69. Revenue beat estimates of $349.2M coming in at $370M displaying a 23% year-over-year increase. Growth was primarily fueled by the robust sales of PYLARIFY and DEFINITY. Strategic investments in the pipeline and business development, including partnerships like Perspective Therapeutics, enhance LNTH's radiopharmaceutical capabilities. Operational excellence and strategic marketing campaigns have solidified PYLARIFY's position as the market leader in PSMA PET imaging. We have other comments posted on our take on the growth. Management did have some issues with forecasting its extremely rapid growth over the past couple of years. But it seems to have learned a few things. It is debt free, with cash, very cheap, and produces solid free cash flow.
Unlock Premium - Try 5i Free
LNTH is now trading at 9.1x times' Forward P/E. In the last few years, revenue and earnings growth were solid, but the share price has been under pressure recently after the company gave out weak preliminary result for FY2023. The balance sheet is strong, with a net debt of only $3M. The company has been reinvesting heavily in the last two years to pursue growth, along with some minor buybacks. Based on consensus estimates, sales are expected to grow by around 9% over the next few years. LNTH is a bit different from LLY and ABBV, which are drug development companies. The momentum is quite poor but we think valuation is quite attractive. It might be a value trap, and we would be less inclined to add until growth picks up or momentum improves.
Unlock Premium - Try 5i Free
- «
- ‹
- 1
- ›
- »
Lantheus(LNTH-Q) Rating
Ranking : 3 out of 5
Bullish - Buy Signals / Votes : 1
Neutral - Hold Signals / Votes : 1
Bearish - Sell Signals / Votes : 1
Total Signals / Votes : 3
Lantheus(LNTH-Q) Frequently Asked Questions
What is Lantheus stock symbol?
Lantheus is a American stock, trading under the symbol LNTH-Q on the NASDAQ (LNTH). It is usually referred to as NASDAQ:LNTH or LNTH-Q
Is Lantheus a buy or a sell?
In the last year, 3 stock analysts published opinions about LNTH-Q. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Lantheus.
Is Lantheus a good investment or a top pick?
Lantheus was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Lantheus.
Why is Lantheus stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Lantheus worth watching?
In the last year, there was no coverage of Lantheus published on Stockchase.
What is Lantheus stock price?
On 2025-07-03, Lantheus (LNTH-Q) stock closed at a price of $80.46.
There has been no material news since our last comment. A couple of lawsuits related to the stock's decline but these are common when a stock drops. The company has presented at a couple of investment conferences but nothing new was revealed. The Life Molecular acquisition has not yet closed but closing was not expected yet. It is very cheap at 11X earnings and technicals show a bit oversold. This week there was disclosure of an insider sale of about $400K. Bloomberg shows 13 analysts, 12 BUY 1 HOLD, target $128.42. It looks attractive IF it does not have to guide lower, again. But it may look better once the acquisition has closed and growth is set to accelerate.
Unlock Premium - Try 5i Free